Почетна › Трипл негативен рак на дојка › Охајо
Клинички испитувања за Трипл негативен рак на дојка во Охајо
29 студии за Трипл негативен рак на дојка бараат учесници на локации во Охајо.
Градови во Охајо
Официјален текст на студијата (англиски)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06465069Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT05422794Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT05867251A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027), Cincinnati
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06966700Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Cleveland Clinic - Mercy Hospital ( Site 0057), Canton
- Tri-County Hematology & Oncology Associates, Inc. ( Site 0076), Massillon
- Taylor Cancer Research Center ( Site 9500), Maumee
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06393374A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Local Institution - 0102, Columbus
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06618287First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care, Inc., Cincinnati
- Ohio State University CRS, Columbus
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT05633654Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT03606967A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- University of Cincinnati Medical Center, Cincinnati
Се регрутираНабљудувачка студија
Возраст од 18 до 99 · Сите полови · Ажурирано 3.9.2026 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Cleveland Clinic, Cleveland
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.8.2026 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07182149Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- The Ohio State University, Columbus
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 13.8.2026 · NCT05985655SMP-3124LP in Adults With Advanced Solid Tumors
- Ohio State University, Columbus
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 12.8.2026 · NCT06526819Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.7.2026 · NCT05208762Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
- MetroHealth, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
Се регрутира
Возраст 18 и постари · Жени · Ажурирано 29.6.2026 · NCT05677802A Study of LY4175408 in Participants With Advanced Cancer
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.6.2026 · NCT07046923I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Cleveland Clinic, Cleveland
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center, Columbus
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT01042379Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- The Christ Hospital Cancer Center, Cincinnati
- Ohio State University Medical Center, Columbus
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 29.4.2026 · NCT04468061Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Се регрутира
Возраст од 40 до 65 · Жени · Ажурирано 11.12.2025 · NCT06582615A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- The Christ Hospital, Cincinnati
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.11.2025 · NCT05902988Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Cleveland Clinic, Cleveland
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 29.10.2025 · NCT06249048A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- The Ohio State University, Columbus
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2025 · NCT06682793A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
- Gabrail Cancer Center Research, Canton
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 19.6.2025 · NCT06568692A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Gabrail Cancer Center, Canton
Се регрутираФаза 3
Возраст од 18 до 65 · Жени · Ажурирано 21.3.2025 · NCT03671044Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.